Bristol Myers Squibb's BMS-986446 receives FDA Fast Track Designation, aiming to transform early Alzheimer disease treatment by targeting tau pathology.
In this CME article, explore the complexities of movement disorders in psychiatric practice, including their causes, symptoms, and treatment strategies for better patient care.